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PATIENTS WITH A HISTORY OF OBESITY OR 
OVERWEIGHT, THEIR TREATMENT, AND 
ASSOCIATED COMORBIDITIES
Starling A, Gaskin M, Harrison P, Thorington N
Disease Treatment and Outcomes Group, IMS HEALTH, 
Middlesex, England
OBJECTIVES: To identify the number of UK patients
who have had a record of obesity or overweight in their
primary care data, together with the treatments em-
ployed, and associated comorbidities.
METHODS: This study used UKPCD which contains lon-
gitudinal records of nearly 2 million patients. Data are
captured daily from General Practitioners using AAH
Meditel System 5 software as part of their standard record
keeping. Patients were selected according to the primary
care coding system “Read” (entered as a problem or prob-
lem-linked note code), or prescribed therapy, from Janu-
ary 1992 to September 1998. Therapies and comorbidities
were extracted from these patients’ records.
RESULTS: Of all the active patients included in the Me-
diPlus database, 22.30% (95% CI 22.20–22.38) had a
mention of obesity or overweight in their patient record.
Of these obese and overweight patients, 1.26% (95% CI
1.22–1.31) were prescribed an anti-obesity drug and
1.87% (95% CI 1.82–1.93) were advised to follow a reg-
imen of diet and/or exercise. The top five comorbidities
most commonly associated with obesity/overweight were
(percentage of the obese/overweight population): hyper-
tension, 97.12% (95% CI 96.97–97.12); arthritis, 58.08%
(95% CI 57.82–58.24); IHD, 23.36% (95% CI 23.18–
23.55); COPD, 18.42% (95% CI 18.25–18.59); diabetes
mellitus, 5.88% (95% CI 5.78–5.99).
CONCLUSION: This study is an example of the use of an
automated, observational, primary care database such as
MediPlus in pharmacoeconomic and outcomes research.
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THE ECONOMIC AND HEALTH BENEFITS OF 
CONVERSION TO NORMAL SINUS RHYTHM
Caro JJ, Migliaccio-Walle K, Klittich WS, O’Brien JA
Caro Research, Concord, MA, USA
It has been well documented that atrial fibrillation (AF)
leads to serious consequences for many who suffer from
it. This has presupposed that conversion to, and mainte-
nance of, normal sinus rhythm (NSR) is beneficial.
OBJECTIVE: The purpose of this study was to compare
the long-term benefits associated with NSR compared
with AF.
METHODS: A state-transition model was developed
which compares an AF cohort to a converted population
in NSR with otherwise identical characteristics. Conse-
quences were grouped into three categories: symptoms
(e.g., palpitation), moderate events/states (e.g., angina),
major events/states (e.g., stroke). In addition, reversion to
AF was allowed for the NSR cohort. Rates of conse-
quences were identified through a review of the literature
and clinical trial data. Cost estimates for all consequences
and maintenance therapy (but not for conversion) were de-
veloped based on data from five all-payer, state discharge
databases using ICD-9 codes to identify disease and proce-
dure level data. These sources were supplemented by fee
schedules, other agency and survey data and the literature.
All costs are reported in 1998 US dollars, adjusted for
medical inflation and cost-to-charge ratios.
RESULTS: Life expectancy increases 1104 years (LYG)
for the 1000 person NSR cohort at a reduced cost of
$3323 per patient. These savings result from 31.9 fewer
major adverse events (death, stroke, ICH). Additionally,
NSR patients are expected to experience 14–33% fewer
days AF-related with symptoms per year.
CONCLUSION: This study suggests that there are sub-
stantial economic and health benefits to converting and
maintaining AF patients in NSR. There remains, how-
ever, a need to study the long term effects in a converted
NSR population as the only available data, to date, are
for native NSR populations.
ECONOMIC AND OUTCOMES ISSUES OF 
PSYCHOLOGICAL/NEUROLOGICAL DISORDERS
PNP1
DEVELOPMENT AND INITIAL VALIDATION OF 
A BRIEF MENTAL HEALTH OUTCOME MEASURE
Lenderking WR1,2, Blais MA2, Leahy L2, Baer L2
1Abt Associates Clinical Trials, Cambridge, MA, USA; 
2Massachusetts General Hospital, Boston, MA, USA
Growing pressure on mental healthcare providers and
managed care organizations to document the effective-
ness of their treatments requires linking improvements in
the process of care with measurement of the outcomes of
care. Outcomes assessment in psychiatry has previously
focused mainly upon specific conditions (such as anxiety
disorders or depression).
OBJECTIVE: We sought to develop a scale that would
be applicable across settings, treatments, and patient di-
agnoses, and would be meaningful to clinicians of differ-
ent theoretical persuasions. Using classical test theory
and Rasch item analysis, we developed a short scale de-
signed to measure the effectiveness of mental health treat-
ment across a wide range of mental health services and
populations.
METHODS: Item development for the scale was guided
by literature review, and interviews with senior clinicians
and patients. We used three different samples of inpa-
tients, outpatients, and non-patients for item reduction,
reliability analysis and validation (total n  257).
RESULTS: We reduced our initial item pool from 81 to
10 items. The 10-item scale had high internal consistency
(Cronbach’s alpha  .96), and showed strong correla-
tions with commonly used measures of psychological
well-being and distress. The Rasch characteristics of the
final 10-item scale were also good. The sample (subject)
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separation was 4.2, the sample  was .94, the item sepa-
ration was 3.0 and the item  was .90.
CONCLUSIONS: Our results suggest that the scale ap-
pears to measure a broad domain of psychological func-
tioning. Moreover, the scale appears to lack ceiling and
floor effects, and discriminated between inpatients, out-
patients, and non-patients, suggesting the scale has excel-
lent potential to be broadly responsive to a variety of
treatment effects.
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IMPACT OF CLINICIAN EDUCATION ON
LONG-TERM ANTIDEPRESSANT PRESCRIBING
Fulop G, Robinson Jr D, Hirsch L, Hensleigh M, Maldonato 
D, Brookler R, Carides P, Kelly M
Merck-Medco Managed Care L.L.C., Montvale, NJ, USA
OBJECTIVE: Measure the impact of a PBM-adminis-
tered depression health management program based on
AHCPR guidelines on the prescribing behavior of clini-
cians using long-term antidepressant therapy.
METHOD: Doctors of patients at least 75% compliant
with antidepressant medication over the last 12 months
were identified (12/97 to 1/98) for a treatment education
intervention. Physicians (n  11,646) were mailed a one-
page summary of the AHCPR depression guidelines, a
patient-specific drug profile and diagnosis survey at the
13th month of antidepressant therapy. Non-responding
clinicians were called by trained pharmacists to secure
patient diagnosis and reinforce guidelines. Patients (n 
16,277) of the intervened-upon doctors were monitored
for antidepressant use at the 17th and 20th months (5
and 8 months after month 12, taken as baseline) follow-
ing their initial prescription. The control group (n 
36,954) was frequency-matched by drug, age, gender,
and region from a PBM prescription claims database.
RESULTS: The predominantly northeastern patient pop-
ulation was 59  13.6 years old and 70% female. With a
24% clinician response rate, 3.4% and 37.1%, respec-
tively, of patients were identified with first or recurrent
episodes of depression, and 29.7% as dysthymic or
chronic. Antidepressant usage was reduced 4.7% com-
pared to controls 5 months after baseline (p  0.001),
and 6.8% at 8 months. Among those identified, 16%
known first-episode, 12% recurrent and 10% dysthymic
depressed patients had discontinued therapy at 5 months.
At 8 months, the proportions were 14%, 15%, and 14%
respectively.
CONCLUSIONS: A PBM-administered guideline-based
depression treatment quality improvement program may
enhance clinical practice and lower the medication cost
of long-term depression therapy. While a higher propor-
tion of first-episode patients discontinued drug therapy at
5 months, the observed trend was not pronounced, possi-
bly due to clinician response bias. Subsequent analyses
will explore the program’s effect on relapse rates and
medical utilization.
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RACIAL AND GENDER DIFFERENCES IN ACCESS 
TO A NEW DRUG THERAPY
Pinto LA1, Schulz RM1, Young V1, Jordan J2
1University of South Carolina, Columbia, SC, USA; 2Glaxo 
Wellcome Inc., Research Triangle Park, NC, USA
Inquiry into racial and gender differences have rarely fo-
cused on prescribing of new drug therapies.
OBJECTIVE: We examined the effect of race and gender
on the likelihood of being prescribed a new antidepres-
sant (fluoxetine versus existing antidepressants) in the
South Carolina Medicaid population.
METHODS: Patients were included in the study if they
had a primary physician or hospital diagnosis of depres-
sion (based on ICD-9-CMs) between January 1, 1988
and December 31, 1990 and if they had filled an antide-
pressant prescription within 4 months following the diag-
nosis. Selection of the study period was based on the year
fluoxetine entered the market (1987). A total of 1447 pa-
tients met the inclusion and exclusion criteria. Racial and
gender differences in prescribing patterns were deter-
mined using logistic regression, controlling for age, type
of county, provider type, Medicaid eligibility, physician
visits, and early filling of prescriptions.
RESULTS: Blacks were 30% less likely than whites
(OR  0.699; CI 0.540, 0.904, p  0.01) and males were
48% less likely than females to receive a fluoxetine pre-
scription.
CONCLUSION: Results demonstrated that there were sig-
nificant racial and gender differences in the utilization of
fluoxetine in the period immediately following its launch.
The findings should be interpreted with caution as poten-
tial confounding by disease severity, patient behavior, and
certain regional characteristics were not controlled.
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ECONOMIC OUTCOMES OF ANTIDEPRESSANT 
USE IN A MANAGED CARE ORGANIZATION
White TJ1, Nichol MB2
1Prescription Solutions—A subsidiary of PacifiCare Health 
Systems, Costa Mesa, CA, USA; 2University of Southern 
California School of Pharmacy, Los Angeles, CA, USA
Managed care organizations are striving to seek ways to
provide cost-effective care for patients with major depres-
sion.
OBJECTIVE: The primary objective is to determine the
relationship between antidepressant utilization patterns
(treatment completion, switching, and augmentation)
and overall healthcare costs from a managed care per-
spective. The secondary objective is to investigate differ-
ences between specific antidepressants regarding these
outcomes. The inquiry is guided by the question: Which
factors contribute to overall healthcare service expendi-
tures for the treatment of depression?
METHODS: Retrospective computerized claims records
from a large managed care organization were analyzed
